Daniel P. Cahill, M.D.,Ph.D.
Co-Author
This page shows the publications co-authored by Daniel Cahill and Julie Miller.
Connection Strength
5.410
-
Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2021 01 30; 23(1):53-62.
Score: 0.918
-
MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro Oncol. 2020 11 26; 22(11):1553-1554.
Score: 0.907
-
Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 05 06; 21(5):669-677.
Score: 0.814
-
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer. 2017 Dec 01; 123(23):4535-4546.
Score: 0.729
-
Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro Oncol. 2022 Mar 03.
Score: 0.247
-
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 11; 10(11):1672-1689.
Score: 0.220
-
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
Score: 0.203
-
Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2019 Jan; 141(2):327-335.
Score: 0.198
-
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathol Commun. 2018 10 17; 6(1):106.
Score: 0.196
-
Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
Score: 0.193
-
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017 Dec 12; 8(65):109228-109237.
Score: 0.184
-
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115.
Score: 0.179
-
Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opin Investig Drugs. 2016 Sep; 25(9):1007-9.
Score: 0.169
-
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Res. 2020 12 01; 80(23):5330-5343.
Score: 0.056
-
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662.
Score: 0.056
-
PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Mol Cancer Ther. 2018 12; 17(12):2551-2563.
Score: 0.049
-
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792.
Score: 0.048
-
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.